NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis $4.32 +0.31 (+7.71%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rezolute Stock (NASDAQ:RZLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rezolute alerts:Sign Up Key Stats Today's Range$3.82▼$4.5450-Day Range$3.84▼$5.0952-Week Range$1.07▼$11.46Volume3.13 million shsAverage Volume2.22 million shsMarket Capitalization$415.32 millionP/E RatioN/ADividend YieldN/APrice Target$10.44Consensus RatingModerate Buy Company Overview Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes. Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar. RZ358 has been evaluated in clinical studies involving children and adults with the condition. The company has also advanced RZ402, an investigational oral plasma kallikrein inhibitor being developed for diabetic macular edema, a vision-threatening complication of diabetes. Rezolute’s pipeline reflects its broader goal of developing treatments that address significant unmet needs in metabolic and related diseases. The company is headquartered in Redwood City, California, and is led by President and Chief Executive Officer Nevan Elam.AI Generated. May Contain Errors. Read More Rezolute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreRZLT MarketRank™: Rezolute scored higher than 64% of companies evaluated by MarketBeat, and ranked 280th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRezolute has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRezolute has a consensus price target of $10.44, representing about 134.2% upside from its current price of $4.46.Amount of Analyst CoverageRezolute has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rezolute's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rezolute are expected to grow in the coming year, from ($0.60) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.49% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 14.84, which indicates bearish sentiment.Change versus previous monthShort interest in Rezolute has recently decreased by 1.08%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.44 News SentimentRezolute has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Rezolute this week, compared to 4 articles on an average week.Search Interest2 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have not sold or bought any company stock.Percentage Held by Insiders14.78% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RZLT Stock News HeadlinesRezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment2 hours ago | finance.yahoo.comRezolute gets FDA nod for pre-BLA meeting despite phase 3 miss — retail expects huge rerating2 hours ago | msn.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)Rezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HIOctober 5 at 8:21 AM | rttnews.comFDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock UpOctober 5 at 8:21 AM | rttnews.comRezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital HyperinsulinismOctober 5 at 7:00 AM | globenewswire.comRezolute consensus price target increased by 18.70% to $9.28October 2 at 1:57 PM | msn.comLake Street Capital Initiates Coverage on Rezolute (NASDAQ:RZLT)October 2 at 1:54 AM | americanbankingnews.comSee More Headlines RZLT Stock Analysis - Frequently Asked Questions How have RZLT shares performed this year? Rezolute's stock was trading at $2.36 at the beginning of 2026. Since then, RZLT shares have increased by 88.9% and is now trading at $4.4590. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings results on Thursday, September, 24th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.05. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO). Company Calendar Last Earnings9/24/2026Today10/05/2026Next Earnings (Estimated)11/05/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RZLT's financial health is in the Green zone, according to TradeSmith. RZLT has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RZLT CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees58Year Founded2010Price Target and Rating Average Price Target for Rezolute$10.44 High Price Target$20.00 Low Price Target$6.00 Potential Upside/Downside+137.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.99% Return on Assets-57.94% Debt Debt-to-Equity RatioN/A Current Ratio9.68 Quick Ratio9.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book4.19Miscellaneous Outstanding Shares96,720,000Free Float82,426,000Market Cap$425.28 million OptionableOptionable Beta0.53 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RZLT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
